World journal of nuclear medicine · 2025
A New Labeling Method of 99m Tc-PSMA-HBED-CC.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Phromphao Benchamat, Shiratori Shuichi
Аннотация
OBJECTIVE: 68 Ga-PSMA-HBED-CC ( 68 Ga-PSMA-11) was approved by the U.S. Food and Drug Administration as the first prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging drug for patients with prostate cancer. However, the utility of 68 Ga-PSMA-HBED-CC may be limited due to PET/CT or PET/MR accessibility and 68 GaCl 3 availability produced from 68 Ge/ 68 Ga generator or cyclotron. Thus, in-house preparation of 99m Tc-PSMA-HBED-CC was developed as an alternative to 68 Ga-PSMA-HBED-CC to be ubiquitous and affordable in the worldwide population.
METHODS: A solution of 99m Tc-pertechnetate was added to PSMA-HBED-CC and 4% SnCl 2 ·2H 2 O in a 10-mL sterile vial. The mixture was heated at 100°C for 15 minutes and then allowed to cool to room temperature. Labeling conditions were optimized to maximize the radiochemical yield of 99m Tc-PSMA-HBED-CC. The chelation completeness was monitored using instant thin layer chromatography, and the stability of 99m Tc-PSMA-HBED-CC was subsequently evaluated.
RESULTS: The radiolabeling of 99m Tc-PSMA-HBED-CC was successful using the appropriate amount of 10 µg PSMA-HBED-CC 3 µg SnCl 2 ·2H 2 O and 99m Tc-pertechnetate 370 MBq at 100°C for 15 minutes, yielded the best result in high radiochemical yield (71.49 ± 2.42%), radiochemical purity (98.29 ± 2.65%), and specific activity of 37.84 ± 1.47 GBq/µmol. 99m Tc-PSMA-HBED-CC is stable with radiochemical purity of more than 95% within 4 hours at room temperature.
CONCLUSION: A new labeling method of 99m Tc-PSMA-HBED-CC was developed. Quality control parameters of 99m Tc-PSMA-HBED-CC met the criteria in accordance with the European Pharmacopoeia.
METHODS: A solution of 99m Tc-pertechnetate was added to PSMA-HBED-CC and 4% SnCl 2 ·2H 2 O in a 10-mL sterile vial. The mixture was heated at 100°C for 15 minutes and then allowed to cool to room temperature. Labeling conditions were optimized to maximize the radiochemical yield of 99m Tc-PSMA-HBED-CC. The chelation completeness was monitored using instant thin layer chromatography, and the stability of 99m Tc-PSMA-HBED-CC was subsequently evaluated.
RESULTS: The radiolabeling of 99m Tc-PSMA-HBED-CC was successful using the appropriate amount of 10 µg PSMA-HBED-CC 3 µg SnCl 2 ·2H 2 O and 99m Tc-pertechnetate 370 MBq at 100°C for 15 minutes, yielded the best result in high radiochemical yield (71.49 ± 2.42%), radiochemical purity (98.29 ± 2.65%), and specific activity of 37.84 ± 1.47 GBq/µmol. 99m Tc-PSMA-HBED-CC is stable with radiochemical purity of more than 95% within 4 hours at room temperature.
CONCLUSION: A new labeling method of 99m Tc-PSMA-HBED-CC was developed. Quality control parameters of 99m Tc-PSMA-HBED-CC met the criteria in accordance with the European Pharmacopoeia.